Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes.

Ildiko LingvayNadine Beetz Regina Sennewald Annette Schuler-Metz Julia BertulisChristina LoleyBenjamin LangCaroline LippertJisoo LeeLinda Shapiro ManningDerek Terada

Published in: Postgraduate medicine (2020)

The evaluated doses of empagliflozin/linagliptin/metformin XR FDC tablets were bioequivalent to the corresponding free combinations. Based on these two bioequivalence studies and existing phase 3 data, the FDA has recently approved this triple FDC to improve glycemic control in adults with T2D.

Keyphrases

glycemic control
type diabetes
blood glucose
weight loss
electronic health record
insulin resistance
big data
case control
machine learning